Abliva AB
Records under this name other than the patents Abliva AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 10 patents it holds.
Showing 1 to 3 of 3 · Back to Abliva AB
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,670,175 | Protected succinates for enhancing mitochondrial ATP-production Lapsed on the fee record Ended Jun 6, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 6, 2025 | From the USPTO record |
| US 10,857,150 | Use of sanglifehrin macrocyclic analogues as anticancer compounds Lapsed on the fee record Ended Dec 8, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 8, 2024 | From the USPTO record |
| US 9,504,728 | Dosage form Lapsed on the fee record Ended Nov 29, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 29, 2024 | From the USPTO record |